stockrow
Friday 6 November 2026
Export TLX’s income statement to Excel — free account
Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited’s revenue for fiscal 2025 (year ended December 2025) was $803.8 million, up 55.6% from fiscal 2024.
9.66
0.24
+2.55%
Follow TLX
Alert me
Telix Pharmaceuticals Limited (TLX) Free cash flow
Telix Pharmaceuticals Limited's free cash flow for fiscal 2025 was −$61.1M, compared with $5.3M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$4.4M. Telix Pharmaceuticals Limited ranks 74th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$61.1M | — |
| FY2024 | $5.3M | (38.99%) |
| FY2023 | $8.7M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $8.2M | — |
| Dec 2025 | −$43.0M | — |
| Jun 2025 | −$6.0M | — |
| Dec 2024 | $18.9M | 26.80% |
| 2 more quarters | Free account |
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| TARS Tarsus Pharmaceuticals, Inc. compare | $32.4M |
| TLX Telix Pharmaceuticals Limited | −$4.4M |
| ELVN Enliven Therapeutics, Inc. compare | −$67.0M |
| CELC Celcuity, Inc. compare | −$192.3M |
| VRDN Viridian Therapeutics, Inc. compare | −$343.4M |
| IDYA IDEAYA Biosciences, Inc. compare | −$349.8M |
| DNLI Denali Therapeutics Inc. compare | −$450.0M |
| VKTX Viking Therapeutics, Inc. compare | −$462.6M |
| DYN Dyne Therapeutics, Inc. compare | −$480.4M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)